Verismo Therapeutics to Present First-in-Human SynKIR™-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and Favorable Safety Profile in Oral Presentation at 68th ASH Annual Meeting

The Quick Take
Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo also presenting two preclinical...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
Rupee extends gains for fourth day, closes at 95.64
The rupee closed at 95.64 on Wednesday, modestly stronger from its previous close of 95.75 after going through a choppy session post the US midterm elections.…
Business
Cathie Wood’s ARK sells SpaceX stock, buys Nurix Therapeutics
Local
Dollar edges lower as US election outcome cheers global markets
Business
